A. D. Douglas

发表

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Nguyen H. Tran, Kathryn Jones, Tao Dong, 2020, The Lancet.

Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies

Katherine E. Wright, M. Higgins, S. Draper, 2014, Nature.

A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis

Z. Xiang, H. Ertl, A. Hill, 2018, bioRxiv.

Subunit Blood-Stage Malaria Vaccines

A. D. Douglas, Alexander D. Douglas, A. Douglas, 2017 .

External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance

Andrea A. Berry, G. Fahle, R. Sauerwein, 2014, PloS one.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.

R. Cortese, A. Nicosia, R. Sinden, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines

P. Borrow, S. Draper, A. D. Douglas, 2016, The Journal of Immunology.

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Assessment of antibody-dependent respiratory burst activity from mouse neutrophils on Plasmodium yoelii malaria challenge outcome

S. Draper, R. Pleass, Emily K. Forbes, 2014, Journal of leukocyte biology.

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Nguyen H. Tran, Andreas C. Themistocleous, P. Klenerman, 2020, Nature Medicine.

(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.

S. Madhi, K. Dheda, P. Aley, 2020 .

Immunological considerations for SARS-CoV-2 human challenge studies

A. Hill, A. D. Douglas, A. Douglas, 2020, Nature Reviews Immunology.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Juliana K. Wambua, J. McCarthy, J. Vekemans, 2017, JCI insight.

Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5

Michel Theron, J. Rayner, A. Holder, 2014, The Journal of Immunology.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.

K. Bojang, A. Hill, P. Milligan, 2011, The Journal of infectious diseases.

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

T. Lambe, M. Baker, K. Ewer, 2022, eBioMedicine.

Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system

M. Higgins, G. Labbé, S. Draper, 2016, Scientific Reports.